BioSpace News Archive

As healthcare workers and residents of long-term care facilities in the United States start receiving their first dose of the Covid-19 vaccine, Creche Innovations, along with a Covid-19 vaccine focus group comprised of physicians, nurses and pharmacists from across the country, have developed the Pandemic Mobile Command Center with built-in MicroCool® Refrigeration to ensure the vaccine cold chain is properly maintained.

Morgellons disease is a rare, controversial, unexplained skin disorder characterized by crawling, sores, crawling sensations on and below the skin, and fiber-like filaments emerging from the sores.

Feminine hygiene products, also referred as menstrual care products, are used by women, some transgender men, and genderqueer population.

ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing. The Company’s rapidly advancing OV programs with Best-in-clas

MJ Biotech Inc. (OTCQB:MJTV), today announced that it has signed an agreement with Invest Africa Global LLC (IAG) to provide PPE and Covid-19 Coronavirus Rapid Test Kits; to the Hospitals and other Medical professionals.

Conformis, Inc. (NASDAQ: CFMS), a leader in patient-specific knee and hip instrumentation and implants, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in two virtual investor conferences in January 2021.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed the Company has entered into a supply agreement with the government of the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine to support the government’s aim of providing vaccines to the public as soon as possible.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with COVID-19 pneumonia demonstrated positive safety and efficacy signals.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today provided an update on the U.S. Food and Drug Administration’s (“FDA”) review of Orphazyme A/S’s (NASDAQ: ORPH) (“Orphazyme”) New Drug Application (“NDA”) for arimoclomol to treat Niemann-Pick Disease Type C (“NPC”).

Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.